Emmessar Biotech & Nutrition Ltd
₹ 43.0
-4.82%
22 Nov
- close price
About
Incorporated in 1992, Emmessar Biotech & Nutrition Ltd is in the business of Healthcare, Fine Chemicals and Renting of Immovable property[1]
Key Points
- Market Cap ₹ 21.5 Cr.
- Current Price ₹ 43.0
- High / Low ₹ 64.0 / 23.7
- Stock P/E 24.8
- Book Value ₹ 15.6
- Dividend Yield 0.00 %
- ROCE 11.4 %
- ROE 10.6 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Stock is trading at 2.77 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -2.33% over past five years.
- Company has a low return on equity of 8.92% over last 3 years.
- Earnings include an other income of Rs.1.98 Cr.
- Working capital days have increased from 81.8 days to 163 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0.58 | 1.37 | 2.19 | 1.98 | 2.61 | 1.27 | 0.63 | 3.40 | 6.99 | 0.36 | 1.02 | 0.56 | 0.83 | |
0.77 | 1.43 | 2.34 | 2.66 | 2.38 | 1.67 | 1.27 | 3.81 | 6.15 | 1.26 | 1.71 | 1.64 | 1.79 | |
Operating Profit | -0.19 | -0.06 | -0.15 | -0.68 | 0.23 | -0.40 | -0.64 | -0.41 | 0.84 | -0.90 | -0.69 | -1.08 | -0.96 |
OPM % | -32.76% | -4.38% | -6.85% | -34.34% | 8.81% | -31.50% | -101.59% | -12.06% | 12.02% | -250.00% | -67.65% | -192.86% | -115.66% |
0.08 | 0.09 | 0.06 | 0.03 | 0.98 | 1.25 | 1.01 | 1.21 | 1.47 | 1.92 | 1.75 | 1.99 | 1.98 | |
Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation | 0.07 | 0.20 | 0.07 | 0.03 | 0.01 | 0.05 | 0.08 | 0.06 | 0.06 | 0.09 | 0.09 | 0.10 | 0.08 |
Profit before tax | -0.18 | -0.17 | -0.16 | -0.68 | 1.19 | 0.80 | 0.29 | 0.74 | 2.25 | 0.93 | 0.97 | 0.81 | 0.94 |
Tax % | 0.00% | 82.35% | -25.00% | -30.88% | 0.00% | -15.00% | -82.76% | -2.70% | 36.00% | 48.39% | 47.42% | 7.41% | |
-0.18 | -0.31 | -0.12 | -0.47 | 1.19 | 0.91 | 0.53 | 0.75 | 1.45 | 0.48 | 0.50 | 0.75 | 0.87 | |
EPS in Rs | -0.36 | -0.62 | -0.24 | -0.94 | 2.38 | 1.82 | 1.06 | 1.50 | 2.90 | 0.96 | 1.00 | 1.50 | 1.74 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | -9% |
5 Years: | -2% |
3 Years: | -57% |
TTM: | -8% |
Compounded Profit Growth | |
---|---|
10 Years: | 16% |
5 Years: | 0% |
3 Years: | -20% |
TTM: | 102% |
Stock Price CAGR | |
---|---|
10 Years: | 17% |
5 Years: | 34% |
3 Years: | 20% |
1 Year: | 65% |
Return on Equity | |
---|---|
10 Years: | 17% |
5 Years: | 15% |
3 Years: | 9% |
Last Year: | 11% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
Reserves | -3.04 | -3.42 | -3.62 | -4.09 | -2.91 | -2.01 | -1.49 | -0.73 | 0.70 | 1.17 | 1.67 | 2.41 | 2.77 |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.00 | 0.00 | 0.00 | 0.08 | 0.11 | 0.00 | |
2.97 | 0.65 | 1.03 | 1.36 | 1.13 | 0.92 | 1.59 | 1.86 | 2.11 | 1.04 | 1.19 | 1.23 | 1.52 | |
Total Liabilities | 4.93 | 2.23 | 2.41 | 2.27 | 3.22 | 3.91 | 5.17 | 6.13 | 7.81 | 7.21 | 7.94 | 8.75 | 9.29 |
1.84 | 1.58 | 1.42 | 0.73 | 0.72 | 2.25 | 1.99 | 1.91 | 1.86 | 2.07 | 2.00 | 1.91 | 1.86 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.80 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
3.08 | 0.64 | 0.98 | 1.53 | 1.69 | 1.65 | 3.17 | 4.21 | 5.94 | 5.13 | 5.93 | 6.83 | 7.42 | |
Total Assets | 4.93 | 2.23 | 2.41 | 2.27 | 3.22 | 3.91 | 5.17 | 6.13 | 7.81 | 7.21 | 7.94 | 8.75 | 9.29 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-0.02 | 0.00 | -0.01 | 0.75 | 0.74 | 0.39 | 1.03 | 0.47 | 2.27 | 0.38 | 0.64 | ||
-0.01 | 0.00 | 0.00 | -0.74 | -0.69 | -0.37 | -1.06 | 0.01 | -2.61 | -0.55 | -0.64 | ||
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||
Net Cash Flow | -0.03 | 0.00 | -0.01 | 0.01 | 0.05 | 0.01 | -0.03 | 0.48 | -0.34 | -0.17 | 0.00 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 1,686.55 | 45.29 | 6.67 | 66.36 | 5.59 | 8.62 | 23.17 | 3.22 | 141.51 | 10.14 | 3.58 | 13.04 |
Inventory Days | 529.25 | 267.67 | 335.80 | 136.88 | 121.67 | 52.14 | 2,049.62 | 272.56 | 7.24 | 196.54 | 127.75 | 164.25 |
Days Payable | 5,146.50 | 121.67 | 150.87 | 76.04 | 76.04 | 5.79 | 1,628.46 | 189.61 | 51.70 | 56.15 | 0.00 | 18.25 |
Cash Conversion Cycle | -2,930.70 | 191.29 | 191.60 | 127.20 | 51.22 | 54.97 | 444.33 | 86.18 | 97.05 | 150.52 | 131.33 | 159.04 |
Working Capital Days | 37.76 | 29.31 | 38.33 | 22.12 | 85.31 | 175.31 | 498.25 | 30.06 | 79.37 | -60.83 | 143.14 | 162.95 |
ROCE % | -8.78% | -9.60% | -10.81% | -39.30% | 80.00% | 31.50% | 17.66% | 25.48% | 45.14% | 15.67% | 15.02% | 11.35% |
Documents
Announcements
-
Newspaper Add
8 Nov - Publication of unaudited financial results for Q3 2024.
-
Announcement under Regulation 30 (LODR)-Resignation of Director
7 Nov - Unaudited financial results for Q2 FY2024.
-
Unaudited Financial Results For The Quarter Ended September 30, 2024
7 Nov - Unaudited financial results for Q2 and H1 2024.
-
Board Meeting Outcome for Unaudited Results
7 Nov - Unaudited financial results for Q2 FY2024.
-
Clarification On Price Movement
7 Nov - Company clarifies no price-sensitive information exists.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
EBNL is a global healthcare company that manufactures and markets healthcare & nutritional products. It fuses various concepts & principles (both ancient & modern) from Biophysics, Biochemistry, Biotechnology and the Indian system of medicine AYUSH (Ayurveda + Yoga + Unani + Siddha + Homeopathy) to create products. This integration resulted in technology called VedaCeuticals which forms the foundation of all products of EBNL